From : National Cancer Institute <nci@updates.cancer.gov>
To : tgabunia@moh.gov.ge
Subject : Pembrolizumab Approved for Esophageal Cancer - Cancer Currents Blog
Received On : 29.08.2019 14:32
Pembrolizumab Approved for Esophageal Cancer - Cancer Currents Blog
National Cancer Institute

Having trouble viewing this email? View it as a Web page.

Bookmark and Share

You are subscribed to Cancer Currents: An NCI Cancer Research Blog from the National Cancer Institute. Recent posts are listed below.

 

 

Pembrolizumab Approved for Some Patients with Advanced Esophageal Cancer
08/28/2019
FDA has approved the immunotherapy drug pembrolizumab (Keytruda) to treat some patients with advanced esophageal cancer. Patients must have certain levels of the protein PD-L1 on their tumors, as determined by an FDA-approved test.
This email was sent to tgabunia@moh.gov.ge using GovDelivery Communications Cloud on behalf of: National Cancer Institute · BG 9609 MSC 9760 · 9609 Medical Center Drive · Bethesda, MD 20892 GovDelivery logo